Agaricus Bisporus and Influenza Vaccination Response

NACompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

May 30, 2024

Conditions
Immune Response
Interventions
BIOLOGICAL

Influenza vaccine

Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine

DIETARY_SUPPLEMENT

Agaricus bisporus capsules

Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily

DIETARY_SUPPLEMENT

Control capsules

Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily

Trial Locations (1)

6229 ER

Maastricht University Medical Center, Maastricht

All Listed Sponsors
collaborator

Scelta Mycofriends B.V.

UNKNOWN

collaborator

CNC Grondstoffen B.V.

UNKNOWN

lead

Maastricht University Medical Center

OTHER

NCT06041867 - Agaricus Bisporus and Influenza Vaccination Response | Biotech Hunter | Biotech Hunter